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INTRODUCTION 
1.  Methylation 
Methylation is the transfer of methyl groups from donor to acceptor molecules. This 
essential biochemical process occurs in every living cell and is catalyzed by enzymes called 
methyltransferases (MTases). Methylation reactions are central to many biological processes 
including small molecule biosynthesis, detoxification, signal transduction, DNA repair, 
epigenetics and transcriptional regulation, translation, and even ageing. Several methyl group 
donors exist in biological systems, but by far the most common one is S-adenosyl methionine 
(SAM) (Schubert et al. 2003). 
1.1  SAM 
SAM is a sulfonium compound which consists of an adenosine moiety attached to a 
methionine molecule (Figure 1). The chemically active methyl group is bound to the sulfonium 
ion, allowing for highly favorable thermodynamics of SAM-dependent methyl-transfer reactions. 
This makes SAM three orders of magnitude more reactive toward polarizable nucleophiles than 
methylated folates, the second most common methyl donors (Cantoni 1975). Besides methyl 
group donation, SAM may also be the source of a variety of other chemical groups, such as 
methylene (in the synthesis of cyclopropyl fatty acids), amino groups (in the synthesis of a biotin 
precursor), ribosyl groups (in the synthesis of epoxyqueueosine in tRNAs) and aminopropyl 
groups (in the synthesis of polyamines). In addition, several [4Fe-4S]-containing enzymes use 
SAM as a source of 5’-deoxyadenosyl radicals, which initiate many pathways by hydrogen-atom 
abstraction (reviewed in Kozbial and Mushegian 2005). Given the variety of processes that SAM 
is involved in, it is unsurprising that this molecule is essential and present in every studied life 
form, and is the second most abundant cofactor in cells, outnumbered only by ATP (Cantoni 
1975).  
Figure 1. Chemical structure of S-adenosyl methionine (SAM). 
The central sulfonium ion is shown in black, the deoxyadenosine in 
blue, the aminocarboxypropyl in magenta, the methyl group in   red. 
Adapted from Fontecave et al. 2004. 
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The metabolism of SAM is a cycle which is a part of the general metabolism of sulfur-
containing amino acid derivatives (Figure 2). Its synthesis is catalyzed by SAM synthetase which 
transfers the adenosyl portion of ATP to a methionine molecule, simultaneously hydrolyzing the 
remaining triphosphate group of ATP to phosphate and pyrophosphate. Following donation of 
the methyl group, the demethylated form of SAM is called S-adenosyl homocysteine (SAH). This 
molecule is subsequently hydrolyzed into homocysteine and adenosine by SAH hydrolase. The 
resulting homocysteine can then either be converted into glutathione, a major cellular antioxidant, 
or be methylated to generate methionine through the action of the MTase methioinine synthase 
which uses 5-methyltetrahydrofolate as methyl donor. The regenerated methionine can then be 
used by SAM synthetase to start the SAM cycle anew. (Mudd and Cantoni 1958, Ludwig and 
Matthews 1997, Palmer and Abeles 1979, reviewed in Fontecave et al. 2004). 
 
 
Figure 2. The SAM cycle. Formation of SAM from ATP and methionine by SAM synthetase (1); transfer of the 
methyl group from SAM to a nucleophile (:Nu) catalyzed by a methyltransferase (2); hydrolysis of SAH into 
homocysteine and adenosine by SAH hydrolase (3); methylation of homocysteine into methionine catalyzed by 
methionine synthase (4). Adapted from Fontecave et al. 2004.  
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1.2  SAM-dependent methyltransferases (MTases) 
MTases catalyze methylation reactions by bringing a SAM molecule containing the 
strongly electrophilic methyl group into close contact with a nucleophilic target (usually S, N, O 
or C atoms), allowing for nucleophilic attack and transfer of the methyl group in an SN2 reaction. 
Collectively, the MTases methylate a very wide range of substrates – from simple molecules such 
as oxidized arsenic, chloride, or iodine ions to complex molecules such as proteins, lipids or 
nucleotides, where methylation may play a structural or regulatory role (Thomas et al. 2004, 
Wuosmaa and Hager 1990, reviewed in Thayer 2002). 
Recent bioinformatical studies have shown that in yeast, as much as 1.2% of the protein-
coding genome is devoted to MTases. In humans, 208 proteins have been identified as known or 
putative MTases, corresponding to almost 1% of all human gene products (Petrossian and Clarke 
2009, Petrossian and Clarke 2011). About 30% of the human MTases (63 proteins) appear to be 
associated with disease, most frequently cancer and mental disorders, underlining the importance 
of such enzymes (Petrossian and Clarke 2011). Interestingly, SAM-dependent methylation 
reactions may be catalyzed by enzymes that have remarkably distinct structures, making 
methylation an excellent example of functional evolutionary convergence.  
 
Figure 3. Human and yeast methyltransferases. Fractional composition of the human (a) and yeast (b) 
methyltransferasomes. Canonical seven-β-strand (7BS) MTases are colored in dark blue, other 7BS MTases in lighter 
shades of blue. SPOUT family in red, SET domain enzymes in yellow. Adapted from Petrossian and Clarke 2011.  
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  1.2.1  Seven β-strand (7BS) MTases 
The first solved MTase structure was that of the HhaI DNA MTase in 1993 (Cheng et al. 
1993). It showed the presence of a seven-stranded β-sheet ending with a reversed β-hairpin, and 
surrounded by α-helices. In the following years, a steady stream of studies reported MTase 
enzymes with similar structures, and for some time, this structural theme was believed to be 
common to all SAM-dependent MTases.    
While many other MTase structural classes have been subsequently described, the Seven 
β-strand (7BS) MTases comprise the most abundant family of MTases and constitute over 60% 
of all human or yeast MTases (Figure 3). These enzymes share little sequence identity but 
contain a characteristic structural core fold consisting of alternating β-strands and α-helices, 
forming a seven-stranded central β-sheet with three helices on each side, similar  to the 
Rossmann fold of NAD(P)-binding proteins (Figure 4). The β-strands are parallel, with the 
exception of the last one which is antiparallel to the rest. Helices Z, A and B are situated on one 
side of the β-sheet, and helices C, D, and E are on the other, with helix C not present in many 
MTases. The N-terminal part of the β-sheet is required for binding to SAM, while the C-terminal 
part is responsible for substrate binding. In addition, the core fold may be surrounded by N- and 
C-terminal extensions, which may also have a function in defining substrate specificity (reviewed 
in Martin and McMillan 2002). 
 
 
Figure 4. The conserved fold of the Seven β-strand (7BS) MTases. Schematic showing the topology of the core 
7BS fold, indicating the SAM- and substrate-binding regions. Helices are shown as rectangles, strands as arrows, the 
N- and C-termini are labelled. Adapted from Martin and McMillan 2002. 
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While the primary amino acid sequence varies greatly between MTases, several conserved 
motifs are present both in the SAM- and substrate-binding regions. The most universal and 
critical for SAM-binding is the glycine-rich GxGxG motif (also referred to as motif I), located in 
the loop between β-strand 1 and α-helix A. These residues interact with the methionine portion 
of SAM. Another conserved motif is an acidic loop between β-strand 2 and α-helix B (motif 
post-I), which forms hydrogen bonds to the hydroxyl groups of the ribose moiety. The substrate-
binding domain of the 7BS MTases also contains the conserved motif II in β-strand 4 and motif 
III between α-helix D and β-strand 5 (Katz et al. 2003, Martin and McMillan 2002). 
However, there are also exceptions to the canonical core fold and motifs. Several human 
MTases have been identified where the core fold is rearranged, the so-called “rearranged 7BS 
MTases”.  For example, in the protein isoaspartyl MTase, the antiparallel β-strands 6 and 7 are 
reversed, and in the protein arginine-specific PRMT3 these strands appear to be completely 
missing (Zhang et al. 2000). In many DNA MTases the overall topology of the fold is circularly 
permutated (Bujnicki 2002). Humans have also several rearranged 7BS MTases whose 
homologues in yeast have been shown to function as RNA methyltransferases (Clancy et al. 2002, 
Bujnicki et al. 2002). Most surprisingly, there are even MTases with a canonical 7BS fold but 
which do not contain the SAM-binding motif I. The human genome appears to encode at least 
two such enzymes, and a sequence homologue of one of them, the yeast YGR001C, has been 
recently shown to methylate a lysine residue in eukaryotic translation elongation factor eEF1A, 
despite previous predictions of DNA N6-adenine methylating activity (Dzialo et al. 2014a, 
Albrecht and Lengauer 2004, Petrossian and Clarke 2011). In addition, several enzymes have 
been described which contain the canonical 7BS MTase fold, yet catalyze the transfer of other 
SAM functional groups than the methyl group. For example, spermidine synthase and spermine 
synthase utilize the aminopropyl group of decarboxylated SAM, and TYW2 catalyzes a SAM-
dependent aminobutyryltransferase reaction during wybutosine synthesis. (Wu et al. 2007, Pegg 
and Michael 2010, Rodriguez et al. 2012).  
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  1.2.2  Other MTase superfamilies 
Another abundant family of MTases are the SET-domain enzymes. The SET domain was 
first recognized as a conserved sequence in several D. melanogaster proteins: Suppressor of 
variegation 3-9, Enhancer of zeste, and Trithorax (Tschiersch et al. 1994, Jones and Gelbart 1993, 
Stassen et al. 1995). However, proteins containing such domains have since been found in all 
eukaryotic organisms studied. All MTases of this class characterized so far are lysine-specific, and 
include all but one of the histone lysine MTases, with the exception being the 7BS enzyme Dot1 
(Feng et al. 2002). SET domain proteins make up 27% of all human MTases, but only 14% of the 
S. cerevisiae MTases (Figure 3), reflecting the redundancy of many of the histone-specific MTases 
in humans. Several SET-domain proteins also have non-histone targets, and the most 
promiscuous of them, SETD7, in addition to methylation of histone H3 at lysine 4, is reported to 
methylate lysine residues in at least 17 other proteins. SETD7 substrates include such key 
proteins as p53, the androgen and estrogen receptors, the transcription factor FoxO3 and DNA 
methyltransferase DNMT1, with lysine methylation affecting their enzymatic activities, 
interactions or stability (reviewed in Herz et al. 2013). 
The SPOUT family is another well-defined and rather large family of MTases, containing 
8 members in humans (Petrossian and Clarke 2011). SPOUT MTases generally modify RNA 
(Tkaczuk et al. 2007). Recently, however, it has been demonstrated that one member of this 
family, the yeast YOR021c (Sfm1) catalyzes the monomethylation of an arginine residue in the 
Rps3p protein of the small ribosomal subunit (Young et al. 2012). This finding suggests a wider 
role for SPOUT methyltransferases than thought previously. 
Additionally, there are several small MTase families with only a few human members. For 
example, the human genome encodes three membrane-bound MTases of unknown function, one 
methyltetrahydrofolate- and cobalamin-dependent methionine synthase involved in the SAM 
cycle, one precorrin-MTase-like diphthine synthase (DPH5) involved in diphthamidation of eEF2, 
and several other putative MTases all of which constitute separate structural families (Petrossian 
and Clarke 2011). 
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2.  Protein methylation 
 Post-translational modification (PTM) of proteins is a common method of controlling 
their structure, localization, stability or activity. PTMs increase the functional diversity of the 
proteome by the addition of functional groups, proteolytic cleavage of regulatory subunits, or 
degradation of entire proteins. In addition to acetylation, phosphorylation, ubiquitination, 
lipidation and glycosylation, the methylation of proteins is one of the most common PTMs. 
Methylation of proteins usually occurs at the N- or C-termini, or on lysine, arginine, histidine, 
proline, glutamine, phenylalanine, asparagine, methionine, glutamate and aspartate residues. Most 
commonly, however, MTases target arginine and lysine residues (reviewed in Karve and Cheema 
2011). 
 
 
 
Figure 5. Publications on lysine and arginine methylation from 1998 to 2013. Chart shows the number of 
publications per year found in PubMed with the search query “lysine methylation” (blue) or “arginine methylation” 
(red) , from 1998 to 2013. Expanded from Paik et al. 2007.  
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While protein methylating (and even demethylating) activity had been isolated from 
cellular fractions many decades ago, and the presence of methylated amino acid residues was 
found to be widely spread across the evolutionary tree, the methylation of proteins did not 
receive considerable attention until recently. This is largely due to the discovery of arginine- and 
lysine-specific MTases that target histone proteins in the early 2000’s. Histone methylation was 
found to play a key role in the “histone code” which regulates chromatin structure and gene 
expression, and has revitalized the field of epigenetics (Greer and Shi 2012). As can be seen from 
Figure 5, since the late 1990’s, the numbers of publications in PubMed on either lysine 
methylation or arginine methylation have exploded. Interestingly, although methylated arginine 
residues are apparently more widespread than methylated lysines in human proteins (Bremang et 
al. 2013) and despite the fact that publications on arginine methylation were proportionally more 
abundant in the late 1990s, research on lysine methylation currently dominates the field. 
2.1  Lysine methylation 
Lysine can be modified with either one, two, or three methyl groups on its ε-amino group 
(Figure 6). Methylation does not change the overall positive charge of the residue, however it 
increases the bulk and hydrophobicity, and full trimethylation makes the positive charge 
permanent. In addition, methylation blocks for other mutually exclusive modifications of lysine, 
most commonly acetylation or ubiquitination (Liu et al. 2014). 
 
 
 
Figure 6. Methylation of lysine. Schematic representation of the chemical structure of the lysine side chain in its 
unmethylated, monomethylated, dimethylated, and trimethylated states. Methylation catalyzed by a lysine 
methyltransferase (KMT).  
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For the first time the presence of methylated lysine residues was observed in the flagellar 
protein of the bacterium Salmonella typhimurium, over 55 years ago (Ambler and Rees 1959). Five 
years later, the first methyllysine residues were discovered in histones isolated from calf thymus, 
wheat germ and rabbit organs (Murray 1964). Subsequently, it was demonstrated that the 
methyllysines present in living organisms could be found in all three possible methylation states, 
i.e. mono-, di-, or tri-methylated. (Paik and Kim 1967, Hempel et al. 1968). Initially, it was unclear 
whether such methyllysine residues were a result of post-translational modification, or whether 
they were pre-formed and incorporated directly into proteins during translation. Finally, in 1970, 
protein lysine-methylating activity was purified from calf thymus and designated as protein 
methylase III, showing that the methylation of lysine residues is an enzymatic, post-translational 
process (Paik and Kim 1970). Interestingly, this enzyme subsequently turned out to be one of the 
lysine-specific histone methyltransferases, SETD7, which methylates histone H3 on lysine 4 in 
addition to lysine residues in various non-histone proteins (Martin and Zhang 2005). Over the 
years, the presence of methyllysine residues was found in a large number of proteins from various 
organisms, including cytochrome c from plants and fungi, mammalian myosin and citrate 
synthase, calmodulin (CaM), and the prokaryotic elongation factor Tu as well as various 
ribosomal proteins (DeLange et al. 1969, Hardy et al. 1970, Bloxham et al. 1981, Watterson et al. 
1980, Ames and Niakido 1979, Dognin and Wittmann-Liebold 1980). However, the responsible 
MTases could not be identified at the time, and besides an indication that lysine-methylation of 
CaM affects its capacity to stimulate NAD kinase activity (Roberts et al. 1986), few biological 
functions have been attributed to these modifications. 
As mentioned above, a whole family of MTases containing the SET domain was 
eventually identified, and these enzymes appear to be devoted entirely to the methylation of 
lysine residues, especially in histone proteins. Additionally, in 2002, a MTase belonging to the 
7BS superfamily, DOT1L, was shown to methylate a lysine residue in the core of histone H3, 
demonstrating that 7BS enzymes may also be lysine-specific (Feng et al. 2002). In 2010, another 
human lysine-specific 7BS MTase had been identified, the elusive CaM MTase (CaM-KMT) 
(Magnani et al. 2010). Subsequently, the numbers of reports describing 7BS MTases which 
methylate lysine residues have steadily increased, and the work in this thesis characterizes the 
activity of several such novel MTases. 
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2.2  Protein demethylation 
Enzymes catalyzing the removal of methyl marks from protein residues also exist. 
Evidence for demethylation of lysine residues in cells was provided already in the early 1960s, 
when an enzyme purified from the rat kidney was shown to liberate lysine from methyllysine in 
the presence of flavin adenine dinucleotide (FAD) and O2 (Kim et al. 1964). This enzyme was 
designated as ε-alkyl-lysinase and is likely to be identical to LSD1, the first protein demethylase 
cloned and characterized over 40 years later (Shi et al. 2004). The demonstration that LSD1 
demethylates mono- or dimethylated lysines 4 and 9 in the histone H3 sparked great interest, as 
methylation of histones was previously thought to be irreversible, and since then, many more 
demethylases have been described. Structurally, the human histone lysine demethylases are a 
diverse group of proteins which can be broadly categorized into two functional enzymatic 
families. The small FAD-dependent amine oxidase family is composed of the enzymes LSD1 and 
LSD2, which are able to demethylate only mono- or dimethylated lysines. The Fe(II) and α-
ketoglutarate-dependent dioxygenase family of proteins containing the catalytic JMJC domain is 
much larger, with at least 30 different human members, and these enzymes are able to 
demethylate also trimethylated lysine residues. The respective demethylation mechanisms of the 
two families are shown in Figure 7. In addition to histones, several demethylases have been 
shown to act on non-histone substrates such as p53, NF-kB, E2F1, DNMT1, and p65 (Reviewed 
in Kooistra and Helin 2012). 
It has also been suggested that arginine residues can be demethylated. A member of the 
Fe(II) and α-ketoglutarate-dependent dioxygenase family mentioned above, JMJD6, has been 
reported by one study to demethylate both symmetrically and asymmetrically dimethylated 
arginine residues, however demethylating activity of this enzyme has never been subsequently 
observed by other groups, and instead JMJD6 has been attributed a role in the lysine 
hydroxylation of RNA splicing factors (Chang et al. 2007, Webby et al. 2009, Hahn et al. 2010). 
However, monomethylated arginine may be converted by deimination into citrulline, a 
modification catalyzed by peptidylarginine deiminases (reviewed in Bicker and Thompson 2013). 
Yet, as no enzyme has ever been found for the conversion of citrulline back to arginine, 
citrullination does not represent a true demethylation process, although it does prevent re-
methylation of the residue, adding a new layer of regulation to the methylation of arginine 
residues.  
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Figure 7. Catalytic mechanisms of lysine demethylation. The two different reaction mechanisms employed by (a) 
the FAD-dependent amine oxidases LSD1 and LSD2 and (b) JMJC-containing Fe(II) and α-ketoglutarate-dependent 
dioxygenases. From Kooistra and Helin 2012. 
 
In addition to the arginine- and lysine-specific demethylases, several demethylases acting 
on other residues have been identified. In E. coli, the enzyme CheB removes the carboxylic 
methyl ester of methylglutamate residues on the methyl-accepting Chemotaxis proteins which 
control bacterial chemotaxis. The reaction occurs through hydrolysis of the methyl ester to form 
glutamate and methanol (Park et al. 2006, West et al. 1995). In eukaryotes, protein phosphatase 
2A (PP2A) is carboxymethylated at the C-terminal leucine residue. This modification is reversed 
by a methylesterase, PME-1, regulating the activity of PP2A (Ogris et al. 1999, Tolstykh et al. 
2000). Furthermore, one of the enzymes required for the biosynthesis of diphthamide, a modified 
histidine residue found only in the eukaryotic elongation factor 2 (eEF2), is a demethylase that 
removes the methyl ether from the methylated diphthine intermediate of the reaction (Lin et al. 
2014). 
 
 
 
 
 
22 
 
 
3.  Methylation of the translation apparatus 
All components of the protein synthesis machinery may be modified by methylation, 
including ribosomal (rRNA), transfer (tRNA) and messenger (mRNA) RNAs, as well as 
ribosomal proteins and various translation factors, impacting the translation process in various 
ways. Strikingly, almost two-thirds of the characterized S. cerevisiae MTases are involved in 
methylating components of the translation apparatus, listed in Table 1 (as of June 2014). About 
two-thirds of the translation associated MTases methylate RNA species, while the rest target 
protein residues.  
Table 
1. S. cerevisiae MTases involved in methylation of translation components. Enzymes are grouped by substrate 
type. Data correct as of June 2014, modified from Dzialo et al. 2014a. 
 
tRNA rRNA mRNA Translation 
factors 
Ribosomal 
proteins 
Trm1 Spb1 Abd1 Mtq1 Hmt1/Rmt1 
Trm2 Nop2  Mtq2 Rmt2 
Trm3 Rrp8  Efm1 Ntm1 
Trm5 Mrm2  Efm2 Hpm1 
Trm7 Dim1  See1 Rkm1 
Trm8 Mrm1   Rkm2 
Trm9 Emg1   Rkm3 
Trm10 Bmt2   Rkm4 
Trm11 Rcm1   Rkm5 
Trm13 Bmt5   Sfm1 
Trm44 Bmt6    
Ppm2 Bud23    
Gcd14     
Tye3     
Trm140     
Ncl1     
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3.1  Methylation of RNA 
The nucleotides of tRNAs are heavily modified, in fact there are about 25-30 different 
types of tRNA modifications in an organism, with an average of 13 modifications spread 
throughout each tRNA in humans (Machnicka et al. 2013). One of the most common is C5-
cytosine methylation, which occurs in various tRNAs and at several positions, and this 
modification was recently linked to the rate of protein synthesis (Tuorto et al. 2012). Other 
modifications contribute to increased tRNA stability and translational fidelity (reviewed in 
Jackman and Alfonzo 2013). 
rRNA may be methylated on the 2’-hydroxyl group of the ribose or at several positions in 
the base, and it is estimated that the human ribosome contains over a hundred such modification 
sites (Maden 1990). These modifications occur largely in the functionally important areas of the 
ribosome, such as the peptidyl transferase center, the A, P and E sites, the polypeptide exit tunnel, 
and at the interface between the large and small ribosomal subunits (Decatur and Fournier 2002). 
Methylation of rRNA plays a role in ribosome biogenesis and activity, impacts the translation of 
certain mRNAs and may be important for proper embryonic development (Liang et al. 2007, 
Sharma et al. 2013, Basu et al. 2011). In bacteria, methylation of rRNA also contributes to their 
resistance to various antibiotics which target the prokaryotic ribosome (Vester and Long 2009).  
Even the mRNA may be methylated, both on the 5’ guanosine cap and at internal 
positions. The most common mRNA modification is N6-Methyladenosine, and it has been 
observed since the 1970s. The recent discovery of the responsible MTases and demethylases, as 
well as “reader”-proteins for such modifications, suggests a possible function for mRNA 
methylation as a mark for post-transcriptional regulation of gene expression (reviewed in Fu et al. 
2014).  
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3.2  Methylation of ribosomal proteins  
At least 15 yeast MTases are involved in the methylation of ribosomal proteins and 
translation factors (Table 1). Of the 10 MTases acting on ribosomal proteins, Rmt1, Rmt2 and 
Sfm1 methylate arginine residues, Ntm1 methylates N-terminal prolines, Hpm1 methylates a 
histidine residue, while the rest, Rkm1-5, methylate lysines.  
Hpm1 is a fascinating enzyme that belongs to the 7BS superfamily. It catalyzes the 
trimethylation of a histidine residue in a ribosomal protein of the large subunit, Rpl3. Histidine 
methylation has been observed in several animal proteins such as actin and myosin but in yeast 
appears to be present exclusively in Rpl3. This modification was shown to contribute positively 
to translational fidelity and proper assembly of the 60S subunit (Al-Hadid et al. 2014). It is 
unknown whether mammalian RPL3 is methylated, but the Hpm1 MTase does have a putative 
homologue in humans, METTL18, which was found to associate with Rpl3 (Cloutier et al. 2013). 
Notably, the METTL18 enzyme is part of the MTase Family 16 (MTF16) subfamily of human 
MTases which is the object of study in this thesis. 
The substrates of the five yeast ribosomal lysine (K) MTases, Rkm1-5, are mostly 
ribosomal proteins of the large subunit, as listed in Table 2. Two of the MTases, Rkm1 and 
Rkm2, each methylate two different lysines within a single protein – Rpl23 or Rpl12, respectively 
(Porras-Yakushi et al. 2005 and 2006). In addition, Rkm1 also monomethylates a lysine residue in 
Rps18 of the small subunit (Couttas et al. 2012). The MTases Rkm3 and Rkm4 both 
monomethylate the same protein, Rpl42, but target different lysine residues (Webb et al. 2008a). 
Uncommon for a lysine MTase, Rkm5, which monomethylates Rpl1, is a 7BS enzyme rather than 
a SET-domain enzyme (Webb et al. 2011). These five MTases are responsible for all of the 
known lysine methylations identified so far in ribosomal proteins of S. cerevisiae, with the 
exception of trimethylation of Rpl11 on lysine 75 (Couttas et al. 2012). Only one of them, Rkm1, 
has a putative homologue in humans, however neither Rpl23 nor Rps18 appear to be methylated 
in mammals, so this pattern of ribosomal lysine methylation is likely to be specific to fungi or 
lower eukaryotes. 
 
 
25 
 
 
Table 2. S. cerevisiae ribosomal lysine MTases. me1 - monomethyl, me2 - dimethyl, me3 - trimethyl, * - has a 
putative human homologue.  
 
MTase Substrate Target residue 
and 
modification 
MTase family 
 Rkm1* Rpl23 
Rps18 
Lys 106 me2 
Lys 110 me2 
Lys 48 me1 
SET 
Rkm2 Rpl12 Lys 3 me2 
Lys 10 me3 
SET 
Rkm3 Rpl42 Lys 40 me1 SET 
Rkm4 Rpl42 Lys 55 me1 SET 
Rkm5 Rpl1 Lys 46 me1 7BS 
 
3.3  Methylation of translation factors 
As of June 2014, five MTases that are involved in the methylation of translation factors, 
including release factors and elongation factors, had been identified in S. cerevisiae (Table 1). Two 
of these target glutamine residues and the remaining three methylate lysines. The Mtq1 and Mtq2 
enzymes are responsible for glutamine methylation of the GGQ motif in two translation release 
factors, the mitochondrial Mrf1p and the cytoplasmic eRF1, respectively (Polevoda et al. 2006). 
The GGQ motif is conserved throughout evolution and is critical for the catalytic activity of 
these release factors, and glutamine methylation of the motif significantly enhances the rate of 
translation termination (Dincbas-Renqvist et al. 2000). It has also been shown that the Mtq2 
MTase has a functional homologue in humans, HEMK2 (Figaro et al. 2008). 
The See1 and Efm1 MTases are responsible for lysine methylation of eukaryotic 
elongation factor 1A (eEF1A) (Lipson et al. 2010). eEF1A is a GTPase that is essential for 
translation with a key role in delivery of tRNA to the ribosomal A-site, but has various other 
functions outside of translation (Lamberti et al. 2004). eEF1A is also one of the most highly 
lysine-methylated proteins (Polevoda and Sherman 2007). Even though yeast eEF1A is highly 
similar to the mammalian protein (81% identical to the rabbit protein), the pattern of lysine 
methylation is quite different. eEF1A from animals may contain up to six methylated lysine 
residues – lysines 36, 55, 79, 165 and 316, and an additional methylation at lysine 290 so far 
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observed only in chick neural crest cells (Cavallius et al. 1993, Vermillion et al. 2014). In yeast, 
eEF1A contains four methylated lysine residues, the lysines 30, 79, 316 and 390 (Cavallius et al. 
1993, Couttas et al. 2012). Thus, only two methylation sites, lysine 79 and lysine 316, are 
conserved from yeast to mammals.  
Efm1 is a SET-domain MTase, which is responsible for monomethylation of lysine 30 in 
yeast eEF1A. While the analogous lysine residue in animal eEF1A is present, it appears to be 
unmodified. There are also no sequence homologues of Efm1 found in higher eukaryotes, 
indicating that this modification may be specific to yeast. (Lipson et al. 2010, Couttas et al. 2012).  
The methylation of lysine 316, on the other hand, is conserved from yeast to mammals, though 
this modification appears to manifest itself as a dimethylation in yeast and as a trimethylation in 
higher eukaryotes (Cavallius et al. 1993). In yeast this methylation is mediated by the See1 MTase 
which belongs to the 7BS superfamily. Its human homologue, METTL10, has been identified as 
a target for phosphorylation during mitosis, suggesting some sort of regulatory mechanism 
(Dephoure et al. 2008). In addition, the methylation of eEF1A lysine 316 was shown to be affect 
the replication of several viruses in yeast and plants, providing a glimpse of its functional role (Li 
et al. 2014). 
The 7BS enzyme Efm2 methylates another yeast elongation factor, the eukaryotic 
elongation factor 2 (eEF2) on lysine 613 (Zhang et al. 2014). eEF2 and its modifications are 
described in detail below, as the identification of another lysine MTase targeting this protein is 
the focus of one of the studies presented in this thesis.  
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4.  Eukaryotic translation elongation factor 2 (eEF2) 
The process of protein synthesis is conventionally divided into the initiation, elongation 
and termination phases. Translation elongation, in turn, can be subdivided into three more stages: 
decoding, transpeptidation and translocation. During decoding, eukaryotic translation elongation 
factor 1 (eEF1) delivers aminoacyl-tRNA to the ribosome which then selects and binds the 
tRNA complementary to the mRNA codon in the ribosomal A site. During transpeptidation, the 
peptidyl group on the P-site tRNA is transferred to the aminoacyl group in the A site through the 
formation of a peptide bond. Finally, in the translocation step, the A-site and P-site tRNAs, 
together with the bound mRNA, are moved to the P site and E site respectively, following which 
the ribosome returns to its pre-translocation state. The process of translation elongation requires 
the participation of several non-ribosomal proteins, or elongation factors, such as the universally 
conserved eEF1A and eEF2 (Voet and Voet 2011).  
Eukaryotic translation elongation factor 2 (eEF2) is a GTPase that catalyzes the 
translocation step of translation elongation by binding to the ribosome and hydrolyzing GTP. 
This enzyme is essential and highly conserved in all eukaryotes, and has functional homologues 
both in archaea (aEF2) and bacteria (EFG). eEF2 is a highly-abundant monomeric protein, 
composed of six structural domains (G’ and I-V), which fall into three distinct structural blocks 
that move relative to each other during eEF2 function (Figure 8) (reviewed in Jørgensen et al. 
2006). eEF2 is subject to several well-studied PTMs 
which are conserved throughout evolution. One is a 
reversible phosphorylation event which impacts 
eEF2 activity, the other is a constitutive formation of 
a unique diphthamide residue the role of which is 
still not entirely clear. Several other modifications of 
eEF2 have also been reported. 
 
Figure 8. Crystal structure of eEF2 in complex with 
sordarin. Colored by domain, sordarin shown in yellow in its 
binding site between domains III, IV and V. Adapted from 
Jorgensen et al. 2003. 
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4.1  Threonine phosphorylation of eEF2 
During the cell cycle or under various stresses, eukaryotic cells may regulate protein 
synthesis at the elongation step by modifying eEF2 activity. The major mechanism for regulation 
of eEF2 is its inactivation through phosphorylation on a threonine residue in its GTP-binding 
domain by a specific Ca2+/calmodulin-dependent kinase, eEF2K, and subsequent reactivation 
through dephosphorylation by protein phosphatase 2 (Ryazanov and Davydova 1989, 
Gschwendt et al. 1989). The eEF2K kinase itself is highly regulated by phosphorylations at 
several sites, downstream of various signaling pathways impacting translation elongation. It is 
negatively regulated by signaling through the mammalian target of rapamycin complex 1 
(mTORC1) and positively regulated through kinases downstream of cAMP, a catabolic signal 
which inhibits protein synthesis, as well as the AMP-activated protein kinase, AMPK, a major 
sensor of low cellular energy status. In addition, eEF2K is dependent on the intracellular levels of 
Ca2+ (reviewed in Kenney et al. 2014). 
4.2  Diphthamidation 
eEF2 is also post-translationally modified by diphthamidation. Diphthamide is present on 
archaeal and eukaryotic EF2 and is the only known modification of its kind. The biosynthesis of 
diphthamide is very complex and involves seven proteins, DPH1-DPH7, one of which is a 
MTase and one a demethylase. Additionally, this process relies on the co-factor SAM, once as a 
source of an aminocarboxypropyl group and subsequently as a source of methyl groups (Figure 
9). 
 
 
Figure 9. Schematic representation of the biosynthesis of diphthamide. Adapted from Lin et al. 2014. 
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The first step of diphthamide biosynthesis involves 4 enzymes, DPH1-4, which transfer 
the aminocarboxypropyl (ACP) group from SAM to the C2 carbon of the imidazole ring. DPH1 
and DPH2 are radical SAM enzymes containing a [4Fe-4S]-cluster, which form a complex and 
use a radical reaction mechanism to transfer the ACP group. DPH3 and DPH4 are thought to 
chaperone the complex (Zhang et al. 2010). The second step again involves SAM, this time as a 
source of methyl groups, and the MTase DPH5, also known as diphthine synthase. DPH5 
trimethylates the amino group of the ACP-histidine from step one, to form diphthine. Some 
ambiguity still surrounds this step, however in 2014 it was suggested that DPH5 in fact creates 
methylated diphthine. That is, DPH5 also catalyzes methylation of the ACP-histidine carboxyl 
group in addition to the trimethylation of the amino group, apparently having an unusual dual 
specificity for methylation of both an N and an O atoms in a single residue. The methylated 
diphthine is then subject to demethylation by the DPH7 demethylase. Lastly, diphthine is turned 
into the final diphthamide product by the ATP-dependent enzyme, diphthamide synthetase, 
DPH6 (Lin et al. 2014, reviewed in Schaffrath et al. 2014). 
The conservation of the diphthamide modification and the maintenance of such a large 
number of genes involved in its synthesis throughout all of eukaryotic evolution underlines its 
fundamental importance. However, its precise biological function is still not well understood 
(reviewed in Su et al. 2013). Diphthamide lies on the tip of domain IV of eEF2, which comes in 
close proximity to the tRNA in the P-site of the ribosome, and appears to interact with two 
universally conserved adenines in 18S rRNA that serve to distinguish cognate from near-cognate 
codon-anticodon pairs (Spahn et al. 2004, Taylor et al. 2007). These interactions may somehow 
stabilize the codon-anticodon duplexes during translocation, thereby preventing frameshifts 
(Jorgensen et al. 2005). The role of diphthamide in maintaining translational fidelity is supported 
by the observation that the lack of this modification results in increased -1 frameshifting during 
protein synthesis (Ortiz et al. 2006). 
Surprisingly, none of the Dph genes in yeast are essential, and their deletion contributes to 
mostly marginal phenotypes. In mammals, however, the deletion of several Dph genes was shown 
to have detrimental effects on development. In mice, homozygous knockout of DPH1 or DPH3 
leads to embryonic death and homozygous DPH5 mutants were retarded in growth and 
development (Chen and Behringer 2004, Liu et al. 2006, Webb et al. 2008b). It is unclear, 
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however, whether these effects are due to decreased translational fidelity or rather due to the loss 
of some other, yet undiscovered function of diphthamide.  
Additionally, the diphthamide residue in eEF2 is a specific target for several bacterial 
toxins, including diphtheria toxin, Pseudomonas exotoxin A and cholix toxin (Jorgensen et al. 
2008). Through ADP-ribosylation of diphthamide, these toxins inactivate eEF2, halting protein 
synthesis and leading to cell death. It has also been suggested that eEF2 may be ADP-ribosylated 
by endogenous ADP-ribosyltransferases in a wide variety of ekaryotic cell types, serving as a 
mechanism regulating cellular protein synthesis (Lee and Iglewski 1984, Sitikov et al. 1984). Later, 
however, this activity was shown to target other eEF2 residues than the diphthamide (Bektas et al. 
2006).  
4.3  Other eEF2 modifications 
In addition to diphthamidation, ADP-ribosylation and EF2K-mediated phosphorylation, 
eEF2 is subject to several other PTMs. Recently, another phosphorylation event was described 
for eEF2. The cyclin A-cyclin-dependent kinase 2 (CDK2) phosphorylates eEF2 on a novel site, 
a serine residue in domain IV, and appears to stimulate eEF2K-mediated threonine 
phosphorylation, possibly by recruiting eEF2K to eEF2 (Hizli et al. 2013) 
As for methylation of eEF2, it has been shown that several arginine residues in eEF2 in 
mouse fibroblast cells become symmetrically dimethylated upon treatment with the basic 
fibroblast growth factor. The biological significance of these methylations is unknown, however 
it was proposed that these methylations are catalyzed by the protein arginine MTase PRMT7, 
with another protein arginine MTase, PRMT5, coordinating the process. Interestingly, the 
methylation also appears reversible, suggesting the involvement of an arginine-demethylase (Jung 
et al. 2011). Additionally, in yeast, eEF2 is the target of a 7BS lysine-specific methyltransferase, 
Efm2, which methylates lysine 613 and may be involved in maintaining translational accuracy as 
the knockout of this gene has been reported to increase the incidence of -1 ribosomal 
frameshifting (Couttas et al. 2012, Dzialo et al. 2014b). 
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5.  Valosin-containing protein (VCP) / p97 
Valosin-containing protein (VCP), also known as p97, is a highly abundant essential 
protein, ubiquitously expressed in all archaeal and eukaryotic cells. It belongs to the AAA+ 
ATPase superfamily (ATPases associated with diverse cellular activities) and participates in a 
multitude of cellular processes. Like most other members of the AAA+ superfamily, VCP 
assembles into oligomeric ring-shaped complexes and uses the energy of ATP hydrolysis to 
structurally remodel client molecules (Erzberger and Berger 2006). VCP has been linked to 
diverse cellular processes including endoplasmic reticulum-associated degradation (ERAD), 
autophagy, post-mitotic membrane fusion, Golgi reassembly, transcription factor regulation, 
chromatin remodelling in response to DNA damage, and aggregate prevention and disassembly 
(Meyer and Weihl 2014). 
A unifying theme of VCP function is ubiquitination and indeed many of the proteins 
associated with VCP, as well as VCP itself, can bind ubiquitin, whereas others are involved in 
further ubiquitination of VCP substrates. VCP segregates the ubiquitinated proteins from their 
environment i.e. multiprotein complexes, membranes, or chromatin. The specificity of VCP in its 
various functions is mediated through an array of adaptor proteins which guide the protein to 
certain complexes or subcellular locations, and different sets of at least 30 cofactors have been 
shown to be responsible for modulating these processes (Schuberth and Buchberger 2008, Yeung 
et al. 2008, Meyer et al. 2012). 
For example, during ERAD, terminally misfolded membrane and luminal proteins in the 
ER are ubiquitinated by membrane-anchored ubiquitin ligases and extracted from the ER into 
the cytosol, where they are subsequently degraded by the proteasome. VCP facilitates this process 
from the cytosolic side by recognizing the ubiquitinated ER proteins and extracting them out into 
the cytosol through the formation of different complexes with several cofactors, including Npl4 
and Ufd1, erasin and ataxin-3. (Ye et al. 2003, Lim et al. 2009, Zhong and Pittman 2006). By 
associating with a different cofactor, the ubiquitin regulator-X (UBX) domain-containing protein 
p47, VCP functions in membrane fusion of the nucleus and of the Golgi cisternae after mitosis 
(Meyer 2005). Very recently, VCP has also been implicated in the DNA damage response, where 
it facilitates the specific extraction of ubiquitilated proteins from chromatin through association 
with the adaptors UBX4 and UBX5 (Dantuma et al. 2014). 
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5.1  VCP structure 
 The VCP protein is divided into four domains - two ATPase domains D1 and D2, which 
in the assembled homohexamer are organized as two stacked rings with a central channel, and the 
regulatory N- and C-terminal domains which are important for association with various 
interacting proteins (Figure 10). Most of the ATPase activity is attributed to the D2 domain, 
whereas the D1 domain is proposed to be primarily structural, facilitating homohexamerization 
of VCP, and exhibits only minor heat-induced ATPase activity (Song et al. 2003). In addition, 
binding, but not hydrolysis, of ATP in the D1 domain appears to regulate the recruitment of 
adaptor proteins to the N-terminal domain, possibly linking VCP function to the metabolic status 
of the cell (Chia et al. 2012). The binding sites in the N- and C-terminal domains facilitate the 
diversity of VCP functions by coordinating its large collection of cofactors. 
 
 
 
Figure 10. Crystal structure of hexameric mouse VCP in presence of ATPγS. One of the protomers is colored 
by domain: N-domain is in red, D1 in green, D2 in blue, C-terminal domain not resolved. Size of the hexamer is 
indicated in Å. From Chapman et al. 2010. 
 
 
 
 
33 
 
 
5.2  Post-translational modifications of VCP 
VCP is subject to many PTMs. A recent study has revealed the presence of acetylation 
and phosphorylation marks on at least 60 VCP residues, including the phosphorylation of 18 
serines, 15 threonines and 5 tyrosines and the acetylation of 22 lysines. Sixteen of these sites are 
clustered in the N-terminal region and sixteen more in a 120aa-long region in the D2 domain, 
while the others are spread throughout the protein. Regrettably, neither the function, nor the 
enzymes responsible for most of these modifications are yet identified (Mori-Konya et al. 2009). 
The phosphorylation of tyrosine 805 in the C-terminus is the most studied VCP PTM 
and has found several functional roles. This modification has been shown to block the binding of 
several VCP-interacting proteins containing the PUB or PUL domains in vitro, suggesting a 
regulatory role in cofactor binding (Zhao et al. 2007, Mullally et al. 2006). The most well-
characterized PUB-containing VCP adaptor protein is Glycopeptide N-glycosidase (PNGase), 
which is involved in the deglycosylation of ERAD substrates. VCP normally interacts with this 
cofactor by inserting tyrosine 805 into a hydrophobic pocket in the PUB domain of PNGase; 
phosphorylation of this residue disrupts the interaction due to the negative charge of the 
phosphate group, leading to electrostatic hindrances within the hydrophobic binding pocket 
(Zhao et al. 2007). It has also been shown that the yeast homologue of VCP, Cdc48, is relocated 
from the cytosol into the nucleus upon phosphorylation of tyrosine 805, and that in mammalian 
cells VCP also appears to shuttle between the nucleus and the cytoplasm, possibly depending on 
tyrosine phosphorylation or some other PTM (Mori-Konya et al. 2009).  
The acetylation of VCP has also been ascribed some functional roles. Mutation of one of 
the acetylation sites, lysine 696, to mimic acetylated and non-acetylated states, was shown to 
increase and decrease VCP ATPase activity, respectively. Given the large number of acetylated 
lysines found in VCP, and its direct association with HDAC6, a histone deacetylase, it is plausible 
that VCP may also be regulated through acetylation (Seigneurin-Berny et al. 2001, Mori-Konya et 
al. 2009).  
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AIMS OF STUDY 
  
 The aim of the research presented in this thesis was to characterize several novel human 
seven-β-strand methyltransferases (MTases) belonging to MTase family 16 (MTF16), primarily 
the enzymes METTL21D (VCP-KMT, Paper I) and FAM86A (eEF2-KMT, Paper II). In short, 
our purpose was to identify the substrates targeted by these enzymes, to show direct MTase 
activity on the substrates in vitro and the presence of such an activity in vivo, to search for the 
presence of functionally homologous MTases in other organisms, and to investigate the 
biological significance of VCP-KMT and eEF2-KMT-mediated methylation by using 
corresponding gene knockout cells. 
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SUMMARY OF PAPERS 
Paper I 
Lysine methylation of VCP by a member of a novel human protein methyltransferase 
family 
In this paper we introduce the 10 members of the human methyltransferase Family 16 (MTF16) 
and demonstrate protein MTase activity for 3 of them: METTL21A, METTL21C, and 
METTL21D. We also show that METTL21D trimethylates a conserved lysine residue in the 
central pore of the molecular chaperone VCP and correspondingly rename the enzyme to VCP-
KMT. Additionally, through the use of bioinformatics and in vitro activity assays, we identify or 
infer the lack of functional VCP-KMT homologues in several eukaryotic organisms. Importantly, 
we show that the ablation of VCP-KMT-mediated methylation via knockout of the VCP-KMT 
gene from several human cell lines reduces their proliferation rate and invasive ability, supporting 
a role for VCP-KMT in cancer metastasis. 
Paper II 
Identification and characterization of a novel evolutionarily conserved lysine-specific 
methyltransferase targeting eukaryotic translation elongation factor 2 (eEF2) 
This study unravels the function of another human member of MTF16, the enzyme FAM86A. 
We show that FAM86A has a functional homologue in S. cerevisiae, and that both of these 
enzymes are able to trimethylate a specific lysine residue in the eukaryotic translation factor eEF2. 
This eEF2-specific activity leads us to rename the human enzyme eEF2-KMT and the yeast 
enzyme Efm3 (Elongation factor methyltransferase 3), according to existing nomenclature. We 
also show that trimethylation of this residue occurs in vivo in yeast, rat, rabbit and human cells. 
Interestingly, in the brain of the rat, eEF2 appears to be hypomethylated, allowing for the 
existence of a regulatory mechanism. In addition, knockout of the gene encoding Efm3 in yeast 
increases sensitivity of the cells to the eEF2-specific inhibitor sordarin and leads to increased -1 
translational frameshifting, showing that lysine trimethylation of eEF2 has important functional 
consequences. 
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DISCUSSION 
1. Characterization of VCP-KMT 
In Paper I, we describe the novel human methyltransferase (MTase) METTL21D (VCP-
KMT) which targets a specific lysine residue in valosin-containing protein (VCP). VCP-KMT was 
initially picked up as a yeast two-hybrid interactant for another enzyme studied in the Falnes 
group at the time, the putative demethylase ALKBH6. Although the interaction was never 
confirmed, it sparked interest in VCP-KMT. Bioinformatic analysis showed that VCP-KMT is 
part of a group of ten closely related human 7BS MTases, annotated as the putative 
Methyltransferase Family 16 (MTF16) (Paper I Table 1, Katz et al. 2003). When we first set out 
to study the MTF16, none of its ten human members had yet been assigned a function. Soon 
after, however, another research group reported that one of these enzymes is the MTase 
responsible for trimethylation of lysine 115 in the Ca2+-sensing protein calmodulin (CaM). CaM 
methylation has been observed in various organisms since the 1980s and was even shown to have 
consequences for CaM function, however the responsible MTase was not identified until 2010 
(Watterson et al. 1980, Roberts et al. 1986, Magnani et al. 2010). Besides CaM-KMT, no function 
had been attributed to the remaining nine human MTF16 members until the publication of 
Paper I. 
1.1 VCP-KMT in vitro activity 
To find the function of this novel MTase, we started out with in vitro assays investigating 
the activity of recombinant VCP-KMT on several types of substrates. We observed that VCP-
KMT was unable to methylate DNA or RNA, but, at high enzyme concentrations and a higher 
than physiological pH of 8.5, had some activity on homopolymers of lysine, as well as on several 
histone proteins, especially histone H2B - the most lysine-rich histone (Paper I Fig. 1). 
Subsequent MS-analysis of the methylated H2B product, however, showed that methyl groups 
were rather evenly distributed amongst all the lysines in the protein, suggesting that this VCP-
KMT activity was not sequence-specific and thus H2B was unlikely to be a bona fide substrate of 
VCP-KMT in vivo. Nevertheless, these preliminary results gave a good indication that VCP-KMT 
is a functional MTase with protein substrates and likely targets lysine residues. 
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To identify the bona fide substrate, we commissioned a yeast two-hybrid screen, with VCP-
KMT as bait and a human placental cDNA library as prey. The screen identified VCP as a high-
confidence VCP-KMT interactant, and we found that recombinant VCP was efficiently 
methylated by VCP-KMT in vitro. Moreover, a truncated version of VCP lacking the D2 and C-
terminal domains (VCPΔD2) was an even better substrate than full-length VCP.  MS analysis of 
the reaction products identified a single trimethylated residue in VCP and VCPΔD2, lysine 315 
(Paper I Fig. 2). When this residue was mutated, VCP-KMT was no longer able to methylate 
VCP, confirming that lysine 315 is the only target residue. Additionally, we investigated the mode 
of substrate recognition for VCP-KMT by monitoring its activity on short peptides containing 
the VCP target lysine and the surrounding region, and on mutant VCPΔD2 where several 
residues adjacent the methylation site were mutated to alanines without changing the target lysine. 
We found that VCP-KMT was unable to methylate the peptides but was just as active on the wild 
type as on the alanine-mutated VCPΔD2. This suggested that VCP-KMT does not recognize a 
specific linear sequence but rather requires a larger three-dimensional structure for substrate 
recognition (Paper I Fig. 2 and Suppl. Fig. S3). 
Lysine 315 lies in domain D1 of VCP and, in the assembled VCP hexamer, is located in 
the inner pore, inaccessible for VCP-KMT. Enhanced activity of VCP-KMT on VCPΔD2, which 
forms a less stable hexamer than the full-length protein, might be explained by more efficient 
disruption of this hexamer by the MTase (Wang et al. 2003). This is further supported by size 
exclusion chromatography which showed that VCP-KMT is unable to form a stable complex 
with full-length hexameric VCP, yet is able to do so with hexameric VCPΔD2 (Paper I Fig. 2D). 
Moreover, VCP-KMT appears to methylate only higher-order aggregates of VCP rather than the 
biologically functional hexamers, whereas VCPΔD2 is an equally good substrate in both forms 
(Paper I Fig. 2E). The inability to disrupt the VCP hexamer may point to that, in vivo, VCP-
KMT acts exclusively on VCP protomers prior to their assembly into hexamers, or to the 
presence of additional factors which are able to disrupt the VCP hexamer and allow access for 
VCP-KMT to its target residue. The latter hypothesis is supported by a subsequent study which 
showed that the UBX domain-containing tethering protein ASPSCR1, which interacts with VCP-
KMT and has previously been implicated in the conversion of VCP hexamers into monomers, 
stimulates the methylation of VCP by VCP-KMT (Orme and Bogan 2012, Cloutier et al. 2013). 
Intriguingly, ASPSCR1 localizes to the ER-to-Golgi intermediate compartment and the ER exit 
sites, and is implicated in the reassembly of the Golgi apparatus following mitosis (Orme and 
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Bogan 2012). Among its multitude of functions, VCP is also a key player in Golgi reassembly, 
and it may be fruitful to investigate whether VCP methylation status affects this process. 
However, it is not unlikely that other proteins in the horde of VCP adaptors involved in other 
processes would also be able to disrupt the hexamer and stimulate VCP-KMT-mediated 
methylation.  
1.2 Biological significance of VCP-KMT activity 
To elucidate the biological function of VCP methylation, we employed zinc-finger 
nuclease technology to disrupt the VCP-KMT gene in several human cancer cell lines. The zinc-
finger nucleases targeted exon 1 of the VCP-KMT gene, generating a double strand break which 
could then be repaired by the process of non-homologous end-joining, which often introduces 
insertional or deletional mutations. Clones with frameshift mutations in all VCP-KMT alleles 
were obtained for HeLa (epithelial), U87-MG (glioma), and the HEK293-derived, 293 T-REx 
Flp-In (kidney) cell lines. In all cases, MS analysis showed that whereas VCP was almost 
exclusively trimethylated on  lysine 315 in wild type cells, consistently with our results from 
various mouse tissues, in the VCP-KMT knockout cells this residue was completely unmethylated 
(Paper I Fig. 3). This confirmed disruption of the VCP-KMT gene in the cell lines and 
demonstrated that VCP-KMT is the enzyme responsible for methylation of this residue in human 
cells. 
We then attempted to use the VCP-KMT knockout cell lines to unravel the biological 
significance of VCP-KMT activity. As VCP is involved in a myriad of different processes, it is 
difficult to address all possible scenarios where its lysine methylation could be of importance. We 
started with some of the best studied processes and checked whether there were any differences 
between the wild type and knockout cells in degradation assays using reporters of the ubiquitin-
proteasome system or when monitoring autophagy by LC3B processing. However, no significant 
differences were detected (Paper I Suppl. Fig. S6 and S7). We also examined the amount, 
complex size and subcellular distribution of VCP in the knockout cells but also found no 
deviation from the wild type. Furthermore, we investigated whether methylation is important for 
VCP ATPase activity. To this end, we purified endogenous VCP proteins from wild type or 
knockout HeLa cells and compared their ATPase activity – yet once again found no appreciable 
difference (Paper I Fig. 5). These results are in contradiction to a later study published by a 
different group claiming that methylation of lysine 315 in VCP inhibits its ATPase activity 
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(Cloutier et al. 2013). However, the authors of that study have assayed the ATPase activity of the 
recombinant VCPΔD2 protein, which lacks the major ATPase domain, D2. The slight difference 
in residual ATPase acitivity of the D1 domain in our experiments could have been masked by the 
overwhelming activity of the D2 domain. Moreover, there is a high degree of communication 
between the ATPase domains of VCP, and it is unclear how informative it is to study the activity 
of just one domain in isolation (DeLaBarre and Brunger 2003).  
 Fortunately, during our struggle to attribute biological meaning to VCP methylation, a 
study was published which demonstrated that expression of VCP-KMT was upregulated in 
several metastatic tumors and was particularly important for migratory behavior and metastatic 
potential (Thiele et al 2011). This led us to investigate whether our VCP-KMT knockout cells 
showed any abnormalities in the proliferation rate, or migratory and invasive abilities. Indeed, the 
VCP-KMT-deficient HeLa and 293 T-Rex Flp-In cells showed a significantly lower proliferation 
rate than the wild type, but the doubling time of U87-MG cells, which grow slowly already in the 
wild type, was not affected by VCP-KMT knockout. U87-MG knockout cells, however, displayed 
decreased migration and invasion rates as compared to the wild type (Paper I Fgure 5). These 
results demonstrated that the disruption of VCP-KMT expression may lead to slower growth and 
decreased migratory and invasive capacity of human cancer cells, providing further support to the 
participation of VCP-KMT in the process of cancer metastasis. 
 The exact mechanism through which VCP-KMT may promote metastasis is unclear. 
Given the invariable trimethylation status of VCP lysine 315 we observe in mammalian cells, this 
is more likely to be a static constitutive modification which subtly optimizes the overall function 
of VCP, rather than a regulatory mark. It is thus possible that higher levels of VCP-KMT 
expression in metastatic cells would ensure optimal VCP methylation and function. Indeed, while 
VCP is one of the most abundant proteins in the cell, VCP-KMT is by far less abundant, and a 
further elevation of VCP expression has been reported in many fast-growing metastatic cancers 
(Braun and Zischka 2008). Alternatively, it is plausible that at high intracellular levels VCP-KMT 
may methylate off-target substrates, for example histone proteins, lysine methylations of which 
have already been linked tightly with cancer (Varier and Timmers 2011). Another possibility is the 
existence of other VCP-KMT bona fide substrates in addition to VCP, increased methylation of 
which contributes to metastasis. To test this hypothesis we have subsequently treated protein 
extracts from HeLa VCP-KMT knockout cells with recombinant VCP-KMT and 3H-SAM. 
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However, analysis of the reaction products by fluorography did not identify any enzyme-specific 
radiolabelled bands other than a single weak band corresponding in size to VCP, suggesting that 
VCP may in fact be the only VCP-KMT substrate (V. Aileni unpublished observation). Further 
experiments are required to elucidate the precise role of VCP-KMT in cancer metastasis. 
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2. Characterization of eEF2-KMT 
 In Paper II, we describe another human MTF16 member, FAM86A (eEF2-KMT), which 
targets a lysine residue in eukaryotic translation elongation factor 2 (eEF2). Interestingly, while 
most mammals have a single eEF2-KMT gene, in humans this gene constitutes a whole family of 
closely-related genomic sequences, Family with sequence similarity 86 (FAM86), and our first goal 
was to determine the ancestral functional sequence. During the evolution of higher primates, the 
eEF2-KMT gene localized into an unstable genomic region, which resulted in the duplication of 
the segment containing eEF2-KMT to multiple locations in the genomes of humans, gorillas and 
chimpanzees (Darai-Ramqvist et al. 2008). The actual copy number is highly variable, however in 
the reference human genome, there are 15 copies of eEF2-KMT spread over 7 chromosomes 
(Paper II Table 1). Most of the eEF2-KMT copies have been pseudogenized. However, three 
genes are reported to be transcribed and contain an intact conserved 7BS MTase core fold - 
FAM86A, FAM86B1 and FAM86B2. By analyzing the degree of purifying selection of 
evolutionarily conserved residues in these sequences, we found that FAM86A is likely to be the 
enzyme containing the evolutionary conserved activity (Paper II Fig. 1). Furthermore, while we 
were able to PCR-amplify FAM86A from HeLa cDNA, we could not amplify any of the 
FAM86B genes. Cloning the FAM86B1 gene from a commercially-available cDNA clone from a 
melanoma cell line led to poor bacterial expression of the recombinant protein which, in addition, 
did not exhibit any detectable MTase activity. All of this allowed us to focus on FAM86A as the 
evolutionarily conserved MTase in this study.  
2.1 Identification of eEF2-KMT activity 
 Based on the activity of other members of the MTF16 family that had already been 
characterized, CaM-KMT and VCP-KMT, as well as HSPA-KMT and KIN-KMT which were 
concurrently studied in our group, we had good indications that eEF2-KMT may also be a 
protein MTase, possibly targeting lysine residues (Magnani et al. 2010, Paper I, Jakobsson et al. 
2013, Ho et al unpublished). To find the substrate, we performed tandem affinity purification of 
eEF2-KMT from a human Flp-In T-Rex HEK293-derived cell line, which identified the 
eukaryotic translation elongation factor 2 (eEF2) as an interacting protein (Paper II Fig. 2A). To 
investigate whether eEF2 was a substrate for eEF2-KMT-mediated methylation, we initially 
attempted to express recombinant human eEF2 in E.coli. However, we were not successful in 
purifying recombinant eEF2 from bacterial cells. We then had to turn to a eukaryotic system for 
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the production of the protein. The yeast S. cerevisiae is one of the best-studied eukaryotes, 
especially in the field of translation, but regrettably we were unable to produce recombinant 
human eEF2 in this organism either. However, as eEF2 is highly conserved down to the lowest 
eukaryotes, there existed the possibility that the yeast protein could work as a substrate for eEF2-
KMT, much like the cross-species methylation of yeast Cdc48 by the human VCP-KMT which 
we demonstrated in Paper I. In addition, the presence of a putative homologue of the eEF2-
KMT enzyme in S. cerevisiae, YJR129c (Efm3), and the wide commercial availability of single-gene 
yeast knockout strains allowed us to study the effects of eEF2-KMT-mediated methylation in a 
simpler biological setting.  
When we performed in vitro methylation assays with recombinant eEF2-KMT and Efm3 
on protein extracts from wild type and efm3Δ yeast cells, we found that eEF2-KMT is in fact an 
eEF2 MTase, that Efm3 is its functional yeast homologue, and that both enzymes trimethylate 
lysine 509 of the yeast eEF2. Correspondingly, MS analysis demonstrated that this mark is 
present in wild type yeast but absent from the efm3Δ knockout. Furthermore, the mutation of 
lysine 509 in eEF2 abolished the activity of both MTases, showing that this residue is the only 
target for these enzymes (Paper II Fig. 2).  
2.2  Biological significance of eEF2-KMT activity 
When analyzing the phenotype of the efm3Δ knockout yeast, we found that neither the 
proliferation rate nor the rate of protein synthesis of the yeast appeared to be affected by the 
knockout of Efm3, suggesting that methylation of eEF2 does not drastically alter its function in 
translation elongation (Paper II Fig. 4A). We also tested whether the efm3Δ knockout strain 
displayed altered sensitivity to drugs inhibiting protein translation. And indeed, we found that the 
knockout strain was more sensitive than the wild type to the eEF2-specific translation inhibitor 
sordarin (Paper II Fig. 4B and C). Sordarin binds to eEF2 in a cleft between domains III, IV 
and V, and locks it to the ribosome, inhibiting translation. One of the contact points to sordarin 
is in close proximity to lysine 509 which lies in a highly conserved α-helix in eEF2 domain III. 
Moreover, a region involved in sensitivity to sordarin has been mapped to an adjacent eEF2 helix 
(Jorgensen et al. 2003, Shastry et al. 2001). The bulky trimethylation mark on lysine 509 may 
weaken the binding to sordarin through steric hindrance in the binding cleft or may alter the 
interaction of eEF2 with the ribosome. Interestingly, presence of the diphthamide residue in 
eEF2, which is located far away from the sordarin binding region at the tip of domain IV and 
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reaches into the ribosomal decoding center during translation, has been shown to increase 
sordarin sensitivity, potentially linking the region around lysine 509 to events occurring in the 
very center of the ribosome (Botet et al 2008).  
 As for direct interactions with the ribosome, the trimethylated lysine 509 appears to be in 
proximity to a ribosomal protein of the small subunit, Rps23. Rps23 has been described as a 
conserved ribosomal “accuracy center” with various mutations contributing to changes in 
translational accuracy (Alksne et al. 1993, Synetos et al. 1996). In addition, hydroxylation of a 
proline residue in Rps23 was shown to either decrease or increase translational accuracy, 
depending on the stop-codon context (Loenarz et al. 2014). The potential interaction of the 
methylated eEF2 lysine with Rps23 led us to investigate whether eEF2 methylation affects 
translational accuracy. Through the use of a dual luciferase assay, we analyzed the frequency of 
frameshift events in wild type and efm3Δ yeast strain during translation of the -1 programmed 
ribosomal frameshifting sequence of the HIV-1 virus and the +1 programmed ribosomal 
frameshifting sequence of the yeast retrotransposable element Ty1. We found that in the efm3Δ 
mutant, the frequency of -1 frameshifting was significantly higher than in the wild type (Paper II 
Fig. 4D), suggesting a role for eEF2 lysine 509 methylation in maintaining translational accuracy. 
A general maintenance role for the modification is supported by the almost invariant 
trimethylation status we observed at this residue both in yeast and mammalian cells. 
Programmed ribosomal frameshifting sequences have been extensively studied in the 
context of retroviruses, where a frameshift at the overlap of the gag and pol open-reading frames 
allows expression of the viral Gag-Pol polyprotein and sets a defined cytoplasmic Gag : Gag-Pol 
ratio in the cell (Brierley 1995). Recently, however, in yeast and even mammalian cells such 
endogenous frameshifting sequences have also been shown to have a biological function (Advani 
et al. 2013, Belew et al. 2014). It is possible that under certain circumstances, eEF2 methylation 
could be regulated for the translation of some of the endogenous or invading viral frameshifting 
sequences, while serving to enhance translational accuracy under normal conditions. Further 
studies must be performed to unravel the precise mechanism and significance of eEF2 
methylation, especially in the mammalian systems, yet the apparent conservation of eEF2-KMT 
activity throughout eukaryotic evolution stresses the importance of this modification.     
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2.3  Other eEF2 methylation studies 
Unexpectedly, eEF2 methylation became a hot research topic in 2014. Two other groups 
published similar results almost simultaneously with our Paper II (Zhang et al. 2014, Dzialo et al. 
2014b). Both of these studies, however, focused primarily on the S. cerevisiae homologue of eEF2-
KMT, Efm3, and not on the human eEF2-KMT. The earliest of the studies, published in 
Biochemical and Biophysical Research Communications when Paper II was in the process of 
submission, comes from an Australian group headed by Marc R. Wilkins (Zhang et al. 2014). This 
group has previously extensively studied protein methylation in S. cerevisiae, especially in the 
context of translation, and have recently identified a trimethylated lysine at position 509 and a 
dimethylated lysine 613 in yeast eEF2. In addition, they had previously demonstrated that 
methylation of lysine 613 is abolished upon knockout of the EFM2 gene, but failed to identify 
Efm3 as the MTase responsible for trimethylation of lysine 509 (Couttas et al. 2012, Hart-Smith 
et al. 2014). The other study on Efm3, which was published online on the same day and in the 
same journal as our Paper II, comes from the UCLA-based group of Steven Clarke, one of the 
pioneers of the methylation field (Dzialo et al. 2014b). This group has also long been involved in 
the study of methylation in S. cerevisiae and, amongst a multitude of other discoveries, have 
characterized Efm1, See1 and Efm5, three yeast lysine MTases acting on the translation 
elongation factor eEF1A (Lipson et al. 2010, Dzialo et al. 2014a). 
Both of these recent Efm3 studies started with screening single gene knockout strains of 
putative S. cerevisiae MTases by immunoblotting whole cell lysates with antibodies against various 
lysine methylation states. This led them to notice that efm3Δ strains showed reduction of 
methylation signal from the eEF2 region in the blots, and subsequent MS analysis confirmed that 
these knockout strains lack trimethylation of eEF2 lysine 509 which is present in wild type yeast. 
The Australia-based (Zhang et al. 2014) study also included experiments with recombinant yeast 
eEF2 expressed and purified from a knockout strain, demonstrating direct MTase activity of 
Efm3 in vitro. The authors also suggested the human eEF2-KMT to be the functional homologue 
of Efm3, however their conclusions are based on indirect evidence from literature, and they do 
not demonstrate any enzymatic activity of eEF2-KMT to support their claims. We, however, 
clearly show the specific activity of human eEF2-KMT both on the yeast lysine 509 and the 
analogous lysine 525 in human eEF2, establishing beyond a doubt that these two enzymes are 
functional homologues (Paper II Fig. 2 and 3). 
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In addition to Efm3, the UCLA-based (Dzialo et al. 2014b) study also investigated the 
biological significance of the other eEF2 MTase in yeast, Efm2, which targets lysine 613 in the 
yeast eEF2. The methylation of this residue appears to have a similar effect to Efm3-mediated 
methylation, as both the efm2Δ and efm3Δ knockout strains exhibited altered sensitivity to the 
same translation inhibitor drugs - cycloheximide, verrucarin, and tunicamycin. During our studies 
of eEF2-KMT, we were also intrigued by the report implicating Efm2 in eEF2 lysine methylation 
activity (Couttas et al. 2012). Consequently, we have cloned and expressed this enzyme. 
Treatment of yeast eEF2 with recombinant Efm2 confirmed that this enzyme does in fact 
methylate eEF2. Surprisingly, Efm2 showed higher activity on arginine and alanine mutants of 
lysine 509 than on wild type eEF2, which may suggest some cross-talk between the methylations 
at lysine 613 and lysine 509. We also found that the residue analogous to lysine 613 is conserved 
in human eEF2, and that recombinant Efm2 is able to methylate endogenous human eEF2 at 
this residue. A human orthologue of this MTase, however, is unlikely to exist, as MS analysis 
revealed that this residue is completely unmodified in several human cell lines (Davydova et al. 
unpublished observation). Since the activity of Efm2 had already been reported and since this 
MTase appears to be specific to yeast, we chose to solely focus on the characterization of Efm3 
instead.  
 An important difference from our findings is the observation by Dzialo et al. that 
knockout of Efm3 does not increase translational frameshifting, whereas we do see increased -1 
frameshifting in the efm3Δ strain, as compared to the wild type. This may be explained by the 
different -1  programmed ribosomal frameshifting sequences used in the dual luciferase assays, as 
the other group used the fungal L-A virus sequence, whereas we employed the HIV-1 sequence. 
Generally, programmed -1 ribosomal frameshifting signals contain several common features, a 
heptameric “slippery site” followed by a downstream RNA secondary structure which stalls the 
ribosome over the slippery site as it unwinds the RNA. The slippery site usually has the 
consensus form of X XXY YYZ, where X can be any three identical nucleotides, Y can be three 
A or U nucleotides, and Z is either A, U, or C. The downstream RNA secondary structure is 
typically an RNA pseudoknot located 5-9 nucleotides downstream of the slippery site. The 
pseudoknot is thought to pause the translating ribosomes with their A- and P-site tRNAs over 
the slippery site, where they can re-pair with the -1 frame codons, after which translation resumes 
in the new reading frame (Jacks et al. 1988, Dinman et al. 2002). While the yeast L-A virus 
contains a typical pseudoknot downstream of the slippery site, the HIV-1 frameshifting signal 
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appears to contain a different kind of RNA structure, possibly an RNA triplex or two helices 
(Dinman et al. 1991, Dinman et al. 2002, Dulude et al. 2002).  The L-A virus and the HIV-1 
signals also differ slightly in the slippery site sequence, and could conceivably induce 
frameshifting through somewhat different mechanisms which are affected in different ways by 
the methylation status of lysine 509 in eEF2. In addition, while we did not investigate possible 
frameshifting effects of Efm2-mediated methylation of eEF2 lysine 613, Dzialo et al. reported 
that efm2Δ yeast displayed increased -1 frameshifting of the L-A virus sequence, as compared to 
the wild type (Dzialo et al. 2014b). It is thus possible that methylation of eEF2 at two different 
sites, mediated by either Efm2 or Efm3, may control different aspects of ribosomal frameshifting 
in yeast. Further studies must be performed to investigate whether the two eEF2 methylations 
are interconnected in yeast and why Efm2-mediated methylation may not be present in higher 
eukaryotes.  
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3. The human Methyltransferase family 16 (MTF16) 
 The enzymes VCP-KMT and eEF2-KMT constitute a part of the human MTase family 
MTF16 (Paper I Table 1, Katz et al. 2003). All ten members of this family invariably retrieve 
each other as best hits in BLAST searches and, in addition to the secondary structure and 
conserved motifs characteristic for most 7BS MTases, contain a specific [D/E]XX[Y/F]  motif 
located C-terminally of motif II in the loop between strand 4 and helix D (Paper I Fig. 6A). 
Based on the activity of VCP-KMT and CaM-KMT, the earliest characterized members of 
MTF16, this motif initially appeared to be involved in specific interactions with a lysine residue. 
However, one of the uncharacterized members of the MTF16, METTL18, contains this motif, as 
does its yeast sequence homologue, Hmt1, which has been shown to monomethylate a histidine 
residue on the N3 atom in the imidazole ring (Al-Hadid et al. 2014), so it may instead be involved 
in more general N-methylation. It is also similar to the conserved [D/N/S]PP[Y/F] motif 
present in the same location of the structural fold in some DNA and protein MTases, which is 
selective for N conjugated to a planar system such as an amide moiety or a nucleotide (Schubert 
et al. 2003). 
 Owing to the work performed in our lab, as well as that of several other groups, most of 
the MTF16 enzymes are now characterized with respect to their target proteins and residues, 
which are listed in Table 3. Six of the ten enzymes (CaM-KMT, eEF2-KMT, ETFβ-KMT, VCP-
KMT and KIN-KMT) have known biological substrates in currently published literature, while 
ongoing research in our group has in addition revealed the biological substrate of the lysine-
specific METTL21B (V. Aileni et al. unpublished). Furthermore, we showed that METTL21C 
automethylates a lysine residue in vitro (Paper I, Fig. 6B). Thus all of the MTF16 enzymes, with 
the possible exception of METTL18, which has a yeast homologue targeting a histidine residue in 
the ribosomal protein Rpl3, and METTL23, the substrate of which remains elusive, are lysine-
specific. 
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Table 3. Human MTF16 enzymes and their substrates. K - lysine, H - histidine, me1 - monomethyl, me3 - 
trimethyl, # -  activity shown for yeast sequence homologue only, XXX - unpublished data. 
 
Human enzyme Alternative 
name 
Substrate Target residue 
and 
modification 
Reference 
C2orf34 CaM-KMT CaM K115 me3 Magnani et al. 2010 
FAM86A eEF2-KMT eEF2 K525 me3 Paper II,  
Zhang et al. 2014,  
Dzialo et al. 2014 
METTL18  -- RPL3 # 
 
H243 me1# Webb et al. 2010,  
Al-Hadid et al. 2014  
METTL20 ETFβ-KMT ETFβ K200 me3  
 
K203 me3 
Malecki et al. 2014, 
 Rhein et al. 2014 
METTL21A HSPA-KMT HSPA8  
and 
homologues 
K561 me3  
and  
analogous 
positions 
Jakobsson et al. 2013,  
Cloutier et al. 2013 
METTL21B  XXX-KMT XXX KXXX Aileni et al. 
unpublished 
 
METTL21C  -- METTL21C K35 me1 Paper I 
METTL21D VCP-KMT  -- K315 me3 Paper I,  
Cloutier et al. 2013 
METTL22 KIN-KMT  -- K135 me3 Ho et al. unpublished, 
Cloutier et al. 2013 
METTL23  --  --  -- -- 
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 Thus far, each MTF16 member appears to be specific to a single substrate protein, with 
the exception of HSPA-KMT which targets one analogous residue in several highly-similar 
Hsp70 proteins (Jakobsson et al. 2013, Cloutier et al. 2013). Additionally, ETFβ-KMT methylates 
two residues in ETFβ, and unpublished research from our group indicates that another MTF16 
enzyme is also able to methylate several lysine residues in one target protein (Malecki et al. 2014, 
Rhein et al. 2014, A. Ho unpublished). Interestingly, most of the enzymes appear to modify their 
target lysines up to full trimethylation, however intermediate mono- and dimethylation states 
have been observed for most of them, and they could have distinct functions. The presence of 
such hypomethylated MTF16 substrates has even been linked to cancer, as is the case for 
dimethylated HSP70 proteins (Cho et al. 2012). 
 Most of the identified MTF16 substrates are highly abundant proteins. For example, 
according to a recent study of the cellular concentration of proteins, VCP, CaM, HSP70 and 
eEF2 are all in the top 1-2% of the most highly expressed proteins. ETF is also rather abundant 
and in the top 15%, and only Kin17 is in the bottom third (Beck et al. 2011). Many of the 
methods employed by us and others for the identification of MTF16 substrates, i.e. fluorography 
of MTase-treated cellular lysates, immunoblots against methylated lysines, affinity purification 
from cells, etc., are biased towards the discovery of more abundant proteins. It is thus not 
unlikely that some of the MTF16 enzymes may have additional, yet undiscovered substrates. In 
fact, upon prolonged exposure of the fluorography film containing eEF2-KMT activity on 
hypomethylated protein extracts from human cancer cell lines, the presence of an additional weak 
substrate band, larger in size than eEF2, becomes apparent. No such band was detected in yeast 
efm3Δ lysates treated with either Efm3 or eEF2-KMT, suggesting that in higher eukaryotes eEF2-
KMT may have other substrates than eEF2 (Davydova et al. unpublished observation). Many 
other protein MTases exhibit a high level of substrate promiscuity. Recently, one MTase, the 
human fibrillarin, previously implicated in the methylation of rRNA, was shown to additionally 
methylate a glutamine residue in the histone H2A, though no direct enzymatic activity on RNA 
has ever been demonstrated for it in vitro (Tollervey et al. 1993, Tessarz et al. 2014). Such findings 
further support the possibility of additional, more obscure and unexpected substrates for some of 
the MTF16 MTases. 
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 3.1 MTF16 and disease 
 While the enzymes METTL21C and METTL23 have not yet been attributed a substrate, 
they have already been implicated in disease. METTL21C was recently suggested to be involved 
in the bone and muscle diseases osteoporosis and sarcopenia. The study reports that knockdown 
of METTL21C led to the inhibition of mouse myoblast differentiation and appears to impact the 
NF-κB signaling pathway (Huang et al. 2014). METTL23 has been shown by two independent 
studies to be important for human cognition, as the disruption of this gene leads to mild 
intellectual disability (Reiff et al. 2014, Bernkopf et al. 2014). Interestingly, METTL23 was found 
to interact with GABPA (GA-binding protein transcription factor, alpha subunit), a component 
of a transcription factor complex regulating the expression of several genes (Rosmarin et al. 2004). 
Overexpression or knockdown of METTL23 led to increased or decreased expression of such 
genes, respectively, suggesting a function of the METTL23 enzyme as a regulator of GABPA. 
METTL23 and GABPA were reported to interact both in a yeast two-hybrid screen and through 
co-immunoprecipitation from a mouse cell line (Reiff et al. 2014). However, it is unclear whether 
GABPA is subject to methylation by METTL23, as there have not yet been reports of any 
methylated residues in GABPA on Phosphosite (Hornbeck et al. 2012), so the observed effect 
may be indirect and downstream of some other protein subjected to METTL23-mediated 
methylation.  
 Other MTF16 MTases have also been linked to disease. VCP-KMT has been implicated 
in tumor metastasis and HSPA-KMT-mediated dimethylation of the heat shock protein HSPA1 
has been suggested as a biomarker for various cancers (Thiele et al. 2011, Cho et al. 2012). The 
evolutionary conservation of eEF2-KMT throughout the eukaryotic kingdom also suggests that 
the alteration of its function is likely to lead to disease. Yeast cells were not greatly affected by the 
knockout of Efm3, the yeast orthologue of eEF2-KMT, however disruption of genes in the 
highly-conserved diphthamide biosynthesis pathway similarly leads to mostly minor phenotypes 
in yeast, whereas in mammalian systems the effects are much more severe, including abnormal 
embryonic development and even lethality in mice (Su et al 2013). A possible regulatory 
mechanism of eEF2 methylation in rat brain further necessitates the use of a murine model to 
study the effects of eEF2-KMT knockout as well as a closer inspection of eEF2 methylation in 
various parts of the mammalian brain.  
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3.2 MTF16 automethylation 
 In Paper I, we measured the automethylation activity of METTL21C in vitro and 
identified a specific lysine residue in the N-terminus of the enzyme as the target for this activity. 
This showed that the enzyme is a functional lysine-specific MTase (KMT). We also observed 
weaker automethylation activity of VCP-KMT, HSPA-KMT (METTL21A) and eEF2-KMT 
(Paper I Fig. 6 and Suppl. Fig. 6, and Davydova unpublished observation). These 
automethylations could be an in vitro artifact of misplaced enzymatic activity in the absence of a 
substrate, or could potentially have biological functions. In the case of METTL21C which 
contains a specific automethylation target lysine residue, this activity could have biological 
function. Indeed, automethylation is biologically relevant for several other MTases. For example, 
while automethylation of the protein arginine MTase CARM1 does not directly alter its enzymatic 
capacity, mutation of the automethylation site results in the impairment of several downstream 
processes, such as CARM1-activated ERα transcription and pre-mRNA splicing (Kuhn et al. 
2011). Moreover, automethylation activity of the lysine-specific histone MTase G9a creates a 
binding site for interacting proteins, whereas automethylation of the arginine-specific PRMT8 
affects its enzymatic activity by decreasing its affinity to SAM (Chin et al. 2007, Dillon et al. 2013). 
It remains to be seen whether automethylation may similarly be a biologically relevant function 
for some of the MTF16 enzymes. 
3.3 Regulatory lysine methylation 
 In several cases, the methylation of lysines may be reversible and have a regulatory 
function as part of a complex signaling network. For example, as part of the "histone code", 
lysine residues in the N-terminal tails of histone proteins are methylated and/or demethylated by 
MTases and demethylases, leading to distinct methylation states of the residues (Black et al. 2012). 
The resulting lysine marks recruit specialized "reader domain" proteins which recognize distinct 
methyllysine states, e.g. proteins containing a Tudor, MBT, PHD, or Chromo domains (Adams-
Cioaba and Min 2009, Rothbart et al. 2013), activating different transcriptional responses. Such 
regulatory lysine methylation mechanisms have also been described outside of the histone code 
(Esteve et al. 2014, Tong et al. 2015). 
 While the extent of VCP lysine trimethylation does not appear to vary in any of the 
mammalian cell cultures and tissues analyzed (Paper I Fig. 3), it is unknown whether it may be 
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regulated in other cell types, under certain conditions or stages of development. We also show 
that a large fraction of eEF2 from rat brain is hypomethylated, in contrast to almost complete 
trimethylation present in other tissues, allowing for the possibility of a regulatory mechanism in 
mammalian brain (Paper II Fig. 3). Notably, a recent study reported that, outside of its 
canonical histone-demethylating function in the nucleus, the cytoplasmic fraction of the lysine-
specific demethylase KDM4A interacts with the translation machinery, impacting the distribution 
of translation initiation factors within polysome fractions (Van Rechem et al. 2015). This leads to 
the possibility that KDM4A or a related demethylase may also target other translation factors, 
such as eEF2 or the heavily methylated eEF1A, as part of a dynamic mechanism. 
 An interesting mechanism involving methylation of lysine residues is the regulation of 
tumor suppressor p53 during the DNA double strand break damage response (Panier and 
Boulton 2014). The reader protein involved in this process, the tandem Tudor domain-containing 
53BP1, is able to oligomerize and has a strong preference for two dimethylated lysines in the C-
terminal domain of p53, as well as dimethylated lysines in several chromatin components such as 
lysine 36 in histone H3, which is also a modification that correlates with DNA damage (Fnu et al 
2011). The mechanism of p53 recruitment to sites of double strand breaks may thus involve 
formation of 53BP1 homodimers which simultaneously interact with a dimethylated lysine in p53 
and dimethylated lysine 36 in histone H3 (Tong et al. 2015). On a larger scale, oligomerization of 
methyllysine reader domains may lead to the existence of an interaction network between various 
lysine-methylated proteins throughout the cell.  
 Conceivably, MTases that bind tightly to their methylated substrates, like some of the 
MTF16 enzymes (Paper II Fig. 2A, Jakobsson et al. 2013, Cloutier et al. 2013), could also act as 
adaptor proteins or form links between their substrates through oligomerization. One enticing 
possibility is that eEF2-KMT, which in humans and other higher primates has several highly 
similar FAM86 sequence homologues some of which contain no apparent eEF2-methylating 
activity (Paper II), could form heterooligomers with the other FAM86 proteins to bridge the 
interaction of eEF2 and some other cellular component. Such an interaction would be specific to 
higher primates and, especially in the context of a possible regulatory mechanism in the 
mammalian brain, could suggest a role for eEF2 methylation in higher brain function. This 
possibility, however, remains to be investigated. 
 
56 
 
 
3.4  Evolutionary conservation of MTF16-mediated methylation 
 Many of the MTF16 enzymes are conserved throughout large parts of the eukaryotic 
kingdom. In most cases, the substrate proteins of these enzymes are present in all eukaryotic 
organisms, however the specific target lysine residues may not be conserved. For example, in 
species where the target lysine in Kin17 is substituted or deleted, like in S. cerevisiae, there also 
appears to be no KIN-KMT sequence homologue present (Cloutier et al 2014). An eEF2 
homologue exists in prokaryotes, yet the lysine analogous to the lysine methylated by eEF2-KMT 
in eukaryotes is absent, and, correspondingly, there are no prokaryotic sequence homologues of 
eEF2-KMT. On the other hand, the target lysines in VCP and Hsp70 proteins appear to be 
invariant and have the potential to be methylated in all eukaryotes, whereas the corresponding 
MTases have a more patchy distribution. Research performed in our lab showed the existence of 
a functional VCP-KMT homologue in C. elegans through an in vitro methylation assay, and allowed 
us to infer the lack of functional VCP-KMT or HSPA-KMT homologues in S. cerevisiae (Paper I 
Fig. 4, Jakobsson et al. 2013 and manuscript in submission). However, it is often difficult to 
predict functional homology based on sequence similarity. For example, human eEF2-KMT is of 
rather low sequence similarity to yeast Efm3, yet Efm3 still contains eEF2-methylating activity, 
whereas VCP-KMT and HSPA-KMT are both highly similar to each other and to the yeast 
protein YNL024c, yet all three have different functions (Paper I Table I, Paper II, Jakobsson et 
al. manuscript in submission). Demonstration of direct MTase activity is thus critical for 
identification of truly homologous enzymes. Three MTases in S. cerevisiae exhibit high sequence 
similarity to human MTF16 members, YNL024c (Efm6), YJR129c (Efm3), and YIL110W 
(Hpm1) (Paper I Table I). All of these have now been attributed a function, but only Efm3 has 
so far been directly shown to have a functional human homologue (Paper II Fig. 2). 
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 In a flurry of publications during the recent months, all of the MTases responsible for 
lysine methylation of both universally conserved translation elongation factors, eEF1A and eEF2, 
have now been described in S. cerevisiae (Table 4). However, only three of these modifications 
appear to be conserved in humans, and the human lysine MTases (KMT) targeting sites not 
present in yeast eEF1A remain elusive. On a global level in yeast, lysine methylation is more 
common than methylation of any other protein residue (Pang et al. 2010, ). This seems to hold 
especially true in the case of translation factors, and only two other MTases acting on such 
proteins have been described in yeast, Mtq1 and Mtq2, which target glutamine residues in 
translational release factors (Polevoda et al. 2006). Interestingly, while methylation of lysine 
residues was previously considered unusual for 7BS MTases, only one of the six elongation factor 
KMTs listed in Table 4 is not part of this class of SAM-dependent MTases. This indicates that 
KMT activity may be quite common for 7BS enzymes, especially in connection with the 
translation apparatus. 
Table 
4. Lysine-specific MTases of the translation factors in S. cerevisiae, their targets and human homologues. 
KMT - lysine-specific MTase. Data correct as of January 2015. 
.  
KMT Alternative 
name 
Target 
residue and 
protein 
 
MTase 
family 
Citation Human 
homologue 
Efm1 YHL039W Lys 30 eEF1A SET Lipson et al 2010 -- 
Efm2 YBR271W Lys 613 eEF2 
Lys 187 eEF3 
7BS Zhang et al 2014, 
Dzialo et al 2014a 
-- 
Efm3 YJR129C Lys 509 eEF2 7BS Paper II 
Zhang et al 2014, 
Dzialo et al 2014a 
eEF2-KMT 
Efm4  YIL064W 
See1 
Lys 316 eEF1A 7BS Lipson et al 2010 METTL10 
Efm5 YGR001C Lys 79 eEF1A 7BS 
nonstandard 
Dzialo et al 2014b N6AMT2 
Efm6 YNL024C Lys 390 eEF1A 7BS Jakobsson et al, 
manuscript in 
submission 
-- 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 In conclusion, the work described in this thesis led to the characterization of several 
MTases belonging to the previously uncharacterized human members of the MTF16 subfamily of 
human 7BS MTases. We showed that two of them, VCP-KMT and eEF2-KMT, trimethylate 
specific lysine residues in the chaperone VCP and the translation elongation factor eEF2, 
respectively. We also indicated that functional homologues for these enzymes are dispersed 
throughout the eukaryotic kingdom. As for the biological significance of these MTases, the 
activity of VCP-KMT was implicated to be important in cancer metastasis, whereas eEF2-KMT 
appears to fine-tune the process of protein synthesis, however future studies must be performed 
to investigate these mechanisms in detail. Currently, several other members of MTF16 remain 
uncharacterized, and some are already linked to human disease, and it is imperative to study these 
enzymes in greater detail. In addition, the human genome still encodes a wealth of other putative 
MTases, and future investigations must identify their biochemical activities and cellular functions. 
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